SNDL reported net revenue of $195.9 million for the quarter ended March 31, marking a 4.4% decline from the prior year. Gross profit fell 6.8% to $52.8 million, but operating loss narrowed to $9.1 million from $12.1 million, driven by the absence of prior restructuring charges and tighter cost controls. The company ended the period with $213 million in unrestricted cash and zero debt, highlighting a strong liquidity position despite negative operating cash flow of $26.7 million.

Vireo Growth entered an all-stock agreement to acquire FLUENT Corp., converting roughly $30 million of FLUENT debt into Vireo equity and granting FLUENT shareholders about 0.07 Vireo shares per FLUENT share. Upon closing—expected late 2026—the combined entity will operate approximately 74 dispensaries in Florida, leveraging scale in the state’s limited-license market. The transaction is subject to shareholder, court and regulatory approvals, and includes pre-closing operational adjustments to improve cash flow.

Aurora Cannabis launched a suite of new high-THC products—including dried flower, pre-rolls and pastilles—in Canada, Europe and Australia, leveraging its GMP-certified manufacturing network. The rollout aims to meet rising patient and prescriber demand through June and reinforce Aurora’s position in regulated medical markets. New cultivars in Germany and expanded potency ranges in Poland are key elements of the European expansion strategy.